Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB123667 mass balance study in healthy males
NCT07218744Phase 1Completed
- Sponsor
- Incyte
- Start
- Nov 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of INCB123667, sponsored by Incyte. Primary endpoints: Total Recovery (Urine + Feces) of the Administered Radioactivity at 2 weeks and Percentage of Total Radioactive Dose in Plasma, Urinary and Fecal Excretion. Started Nov 2025; status: completed.
02
Drugs
INCB123667
Beyond the preview
Go deeper on NCT07218744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07218744.